Barclays
RCEL icon

Barclays’s Avita Medical RCEL Stock Holding History

Barclays’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.92K Sell
2,682
-16,393
-86% -$68.8K ﹤0.01% 4701
2025
Q4 		$65.8K Sell
19,075
-556
-3% -$2.22K ﹤0.01% 4684
2025
Q3 		$100K Sell
19,631
-26,928
-58% -$141K ﹤0.01% 4614
2025
Q2 		$246K Buy
46,559
+17,766
+62% +$129K ﹤0.01% 4152
2025
Q1 		$234K Sell
28,793
-12,236
-30% -$114K ﹤0.01% 3958
2024
Q4 		$525K Buy
41,029
+3,526
+9% +$41.6K ﹤0.01% 3793
2024
Q3 		$402K Buy
37,503
+28,979
+340% +$272K ﹤0.01% 3908
2024
Q2 		$67.5K Sell
8,524
-11,812
-58% -$112K ﹤0.01% 4086
2024
Q1 		$326K Sell
20,336
-14,144
-41% -$229K ﹤0.01% 3847
2023
Q4 		$473K Buy
34,480
+30,143
+695% +$346K ﹤0.01% 3909
2023
Q3 		$63.4K Sell
4,337
-671
-13% -$11.4K ﹤0.01% 3762
2023
Q2 		$85.2K Buy
+5,008
New +$73.5K ﹤0.01% 3618
2022
Q3 		– Sell
-90
Closed – – 5071
2022
Q2 		$0 Sell
90
-3,854
-98% -$23.8K ﹤0.01% 5212
2022
Q1 		$34K Buy
+3,944
New +$36.4K ﹤0.01% 4260

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's RCEL Position: Q1 2026 in Review

Barclays reduced its Avita Medical (RCEL) stake by 86% in Q1 2026, selling an estimated $68.8K and leaving 2,682 shares worth $9.92K. The position accounts for ﹤0.01% of the portfolio, ranked #4701.

Barclays first reported a position in RCEL in Q1 2022 and has held it in 14 quarters since. The position peaked at $525K in Q4 2024. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • Barclays held 2,682 shares of Avita Medical worth $9.92K as of Q1 2026.
  • Barclays sold 16,393 Avita Medical shares in Q1 2026, an estimated $68.8K.
  • Avita Medical made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4701 holding.
  • Barclays first reported a position in Avita Medical in Q1 2022 and has held it in 14 quarters since.
  • Barclays's Avita Medical position peaked at $525K in Q4 2024.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.